William Stohl, MD, PhD

Professor of Medicine

Chief, Division of Rheumatology

Is this your profile? Click to edit

Overview

Dr. Stohl’s research focus is on systemic lupus erythematosus (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); rheumatoid arthritis (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); Sjogren’s syndrome (biomarkers, novel therapeutics); and B cells (basic biology, role in autoimmune diseases, development of targeted therapies).

Dr. Stohl received his M.D. (1977) and his Ph.D. (1979) from the University Pennsylvania.

Awards

University of Pennsylvania School of Medicine: Upjohn Award, 1979
Arthritis Foundation Southern California Chapter: James R. Klinenberg, M.D. Award, 2003

Research Funding

The vital role of BAFF in the development of SLE
NIH · R01AR050193 · May 16, 2006 – Aug 31, 2012 · Role: Principal Investigator
T CELL CYTOLYTIC ACTIVITY IN SLE
NIH · R01AR041006 · Aug 12, 1993 – Jun 30, 2002 · Role: Principal Investigator
POLYMORPHISM WITHIN T4/LEU3 AND SLE
NIH · R23AR036527 · Jan 1, 1986 – Jun 30, 1989 · Role: Principal Investigator

Media

Publications

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther. 2010; 12(2):111.. View in PubMed
Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010 Feb; 62(2):392-401.. View in PubMed
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity. 2010 Feb; 43(1):84-97.. View in PubMed
B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum. 2009 Nov; 60(11):3400-9.. View in PubMed
Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol. 2009 Nov 01; 183(9):6021-9.. View in PubMed
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther. 2009; 11(5):R143.. View in PubMed
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78.. View in PubMed
Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51.. View in PubMed
Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol. 2009 Feb 15; 182(4):2532-41.. View in PubMed
Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. Ann Rheum Dis. 2009 Nov; 68(11):1768-74.. View in PubMed